Using bispecific antibodies to help patients after bone marrow transplants
Bispecific Antibody Maintenance Therapy after Allogeneic Bone Marrow Transplant
['FUNDING_CAREER'] · JOHNS HOPKINS UNIVERSITY · NIH-10889029
This study is looking at a new treatment using special antibodies to help patients who have had a bone marrow transplant for acute leukemias, like acute lymphoblastic leukemia and acute myeloid leukemia, to boost their immune system against any leftover cancer cells and hopefully keep them healthy for longer.
Quick facts
| Phase | ['FUNDING_CAREER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | JOHNS HOPKINS UNIVERSITY (nih funded) |
| Locations | 1 site (BALTIMORE, UNITED STATES) |
| Trial ID | NIH-10889029 on ClinicalTrials.gov |
What this research studies
This research investigates the use of bispecific antibodies as a maintenance therapy for patients who have undergone allogeneic bone marrow transplants for acute leukemias. The approach aims to enhance the immune response against residual cancer cells while minimizing the risk of complications associated with traditional therapies. By focusing on patients with acute lymphoblastic leukemia and acute myeloid leukemia, the study seeks to improve long-term outcomes and reduce the chances of disease relapse. The research is being conducted at Johns Hopkins University, where a team of experts in oncology and hematologic malignancies is involved.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults aged 21 and older who have received an allogeneic bone marrow transplant for acute lymphoblastic leukemia or acute myeloid leukemia.
Not a fit: Patients who have not undergone an allogeneic bone marrow transplant or those with other types of leukemia may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved survival rates and quality of life for patients recovering from acute leukemia after bone marrow transplantation.
How similar studies have performed: Previous research has shown promising results with bispecific antibodies in similar contexts, indicating potential for success in this novel application.
Where this research is happening
BALTIMORE, UNITED STATES
- JOHNS HOPKINS UNIVERSITY — BALTIMORE, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: WEBSTER, JONATHAN ALLEN — JOHNS HOPKINS UNIVERSITY
- Study coordinator: WEBSTER, JONATHAN ALLEN
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.